Search

Your search keyword '"Haddad, Ghassan"' showing total 443 results
Start Over Author "Haddad, Ghassan"
443 results on '"Haddad, Ghassan"'

1. Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial.

Author

Herrmann, Ken, Gafita, Andrei, de Bono, Johann, Sartor, Oliver, Chi, Kim, Krause, Bernd, Rahbar, Kambiz, Tagawa, Scott, Czernin, Johannes, El-Haddad, Ghassan, Wong, Connie, Zhang, Zhaojie, Wilke, Celine, Mirante, Osvaldo, Morris, Michael, and Fizazi, Karim

Subjects
177Lu-PSMA-617, Nomogram, Overall survival, PSA response, Radiographic progression-free survival, VISION trial, mCRPC
Abstract

BACKGROUND: [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolonged life in patients with metastatic castration-resistant prostate cancer (mCRPC) in VISION (NCT03511664). However, distinguishing between patients likely and unlikely to respond remains a clinical challenge. We present the first multivariable models of outcomes with 177Lu-PSMA-617 built using data from VISION, a large prospective phase 3 clinical trial powered for overall survival. METHODS: Adults with progressive post androgen receptor pathway inhibitor and taxane prostate-specific membrane antigen (PSMA)-positive mCRPC received 177Lu-PSMA-617 plus protocol-permitted standard of care (SoC) or SoC alone. In this post hoc analysis, multivariable Cox proportional hazards models of overall survival (OS) and radiographic progression-free survival (rPFS), and a logistic regression model of prostate-specific antigen response (≥50% decline; PSA50) were constructed and evaluated using C-index or receiver operating characteristic (ROC) analyses with bootstrapping validation. Nomograms were constructed for visualisation. FINDINGS: Patients were randomised between June 2018 and October 2019. Data from all 551 patients in the 177Lu-PSMA-617 arm were analysed in multivariable modelling. The OS nomogram (C-index, 0.73; 95% confidence interval [CI], 0.70-0.76) included whole-body maximum standardised uptake value (SUVmax), time since diagnosis, opioid analgesic use, aspartate aminotransferase, haemoglobin, lymphocyte count, presence of PSMA-positive lesions in lymph nodes, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and neutrophil count. The rPFS nomogram (C-index, 0.68; 0.65-0.72) included SUVmax, time since diagnosis, opioid analgesic use, lymphocyte count, presence of liver metastases by computed tomography, LDH, and ALP. The PSA50 nomogram (area under ROC curve, 0.72; 95% CI, 0.68-0.77) included SUVmax, lymphocyte count and ALP. Performances of the OS and rPFS models were maintained when they were reconstructed excluding SUVmax. INTERPRETATION: These models of outcomes with 177Lu-PSMA-617 are the first built using prospective phase 3 data. They show that a combination of pretreatment laboratory, clinical, and imaging parameters, reflecting both patient and tumour status, influences outcomes. These models are important for aiding treatment selection, patient management, and clinical trial design. FUNDING: Novartis.

Published
2024

2. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.

Author

Singh, Simron, Hope, Thomas, Bergsland, Emily, Bodei, Lisa, Bushnell, David, Chan, Jennifer, Chasen, Beth, Chauhan, Aman, Das, Satya, Dasari, Arvind, Del Rivero, Jaydira, El-Haddad, Ghassan, Goodman, Karyn, Halperin, Daniel, Lewis, Mark, Lindwasser, O, Myrehaug, Sten, Raj, Nitya, Reidy-Lagunes, Diane, Soares, Heloisa, Strosberg, Jonathan, Kohn, Elise, and Kunz, Pamela

Subjects
Humans, Consensus, Intestinal Neoplasms, National Cancer Institute (U.S.), Neuroendocrine Tumors, Octreotide, Pancreatic Neoplasms, United States, Clinical Trials as Topic
Abstract

Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs), with several new agents approved for use. Although the treatment options available for patients with well-differentiated neuroendocrine tumors (NETs) have greatly expanded, the rapidly changing landscape has presented several unanswered questions about how best to optimize, sequence, and individualize therapy. Perhaps the most important development over the last decade has been the approval of 177Lu-DOTATATE for treatment of gastroenteropancreatic-NETs, raising questions around optimal sequencing of peptide receptor radionuclide therapy (PRRT) relative to other therapeutic options, the role of re-treatment with PRRT, and whether PRRT can be further optimized through use of dosimetry among other approaches. The NET Task Force of the National Cancer Institute GI Steering Committee convened a clinical trial planning meeting in 2021 with multidisciplinary experts from academia, the federal government, industry, and patient advocates to develop NET clinical trials in the era of PRRT. Key clinical trial recommendations for development included 1) PRRT re-treatment, 2) PRRT and immunotherapy combinations, 3) PRRT and DNA damage repair inhibitor combinations, 4) treatment for liver-dominant disease, 5) treatment for PRRT-resistant disease, and 6) dosimetry-modified PRRT.

Published
2023

3. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.

Author

Eads, Jennifer, Halfdanarson, Thorvardur, Asmis, Tim, Bellizzi, Andrew, Bergsland, Emily, Dasari, Arvind, El-Haddad, Ghassan, Frumovitz, Michael, Meyer, Joshua, Mittra, Erik, Myrehaug, Sten, Nakakura, Eric, Raj, Nitya, Soares, Heloisa, Untch, Brian, Vijayvergia, Namrata, and Chan, Jennifer

Subjects
high-grade, neuroendocrine carcinoma, neuroendocrine tumors, recommendations, Humans, Female, Neuroendocrine Tumors, Consensus, Neoplasm Grading, Carcinoma, Neuroendocrine, North America, Pancreatic Neoplasms
Abstract

High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an overall lack of prospectively collected data available to advise practitioners as to how best to manage these patients. As a result, best practices are largely based on expert opinion. Recently, a distinction was made between well-differentiated high-grade (G3) neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas, and with this, pathologic details, appropriate imaging practices and treatment have become more complex. In an effort to provide practitioners with the best guidance for the management of patients with high-grade neuroendocrine neoplasms of the gastrointestinal tract, pancreas, and gynecologic system, the North American Neuroendocrine Tumor Society convened a panel of experts to develop a set of recommendations and a treatment algorithm that may be used by practitioners for the care of these patients. Here, we provide consensus recommendations from the panel on pathology, imaging practices, management of localized disease, management of metastatic disease and surveillance and draw key distinctions as to the approach that should be utilized in patients with well-differentiated G3 neuroendocrine tumors vs poorly differentiated neuroendocrine carcinomas.

Published
2023

4. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy

Author

Gudenkauf, Lisa M, Chavez, Melody N, Maconi, Melinda Leigh, Geiss, Carley, Seyedroudbari, Ameen, Thin, Pan, Hoogland, Aasha I, Nguyen, Kathleen, Murthy, Vishnu, Armstrong, Wesley R, Komrokji, Khaled, Oswald, Laura B, Jim, Heather SL, El-Haddad, Ghassan, Fendler, Wolfgang P, Herrmann, Ken, Cella, David, Czernin, Johannes, Hofman, Michael S, Dicker, Adam P, Calais, Jeremie, Tagawa, Scott T, and Gonzalez, Brian D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prostate Cancer, Urologic Diseases, Good Health and Well Being, Male, Humans, Prostatic Neoplasms, Radioisotopes, Patient Reported Outcome Measures, genitourinary oncology, radionuclide therapy, radiophar, maceuticals, patient -reported outcomes, prostate cancer, radionu, clide therapy, patient-reported outcomes, radiopharmaceuticals, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first 177Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. Methods: We identified relevant symptoms and toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) with patient input. Results: This multistep process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The FACT-RNT is a new standardized tool to monitor relevant symptoms and toxicities among PC patients in RNT trials and real-world settings.

Published
2023

8. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE

Author

Strosberg, Jonathan R, Srirajaskanthan, Rajaventhan, El-Haddad, Ghassan, Wolin, Edward M, Chasen, Beth A, Kulke, Matthew H, Bushnell, David L, Caplin, Martyn E, Baum, Richard P, Hendifar, Andrew E, Öberg, Kjell, Ruszniewski, Philippe, Santoro, Paola, Broberg, Per, Leeuwenkamp, Oscar R, and Krenning, Eric P

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Chronic Pain, Digestive Diseases, Pain Research, NETTER-1, Neuroendocrine, Oncology: Endocrine, Radionuclide Therapy, lutetium-177, neuroendocrine, symptom diary, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

We report the impact of 177Lu DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors (NETs) often find burdensome. Methods: All patients enrolled in the international randomized phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial (177Lu-DOTATATE plus standard-dose octreotide long-acting repeatable [LAR], n = 117; high-dose octreotide LAR, n = 114) were asked to record the occurrence of predefined symptoms in a daily diary. Change from baseline in symptom scores (mean number of days with a symptom) was analyzed using a mixed model for repeated measures. Results: Patients (intent-to-treat) who received 177Lu-DOTATATE experienced a significantly greater decline from baseline in symptom scores than patients who received high-dose octreotide LAR. For 177Lu-DOTATATE, the mean decline in days with abdominal pain, diarrhea, and flushing was 4.10, 4.55, and 4.52 days per 4 weeks, respectively, compared with 0.99, 1.44, and 2.54 days for high-dose octreotide LAR. The mean differences were 3.11 days (95% confidence interval, 1.35-4.88; P = 0.0007) for abdominal pain, 3.11 days (1.18-5.04; P = 0.0017) for diarrhea, and 1.98 days (0.08-3.88; P = 0.0413) for flushing, favoring 177Lu-DOTATATE. A positive repeated measures correlation was found between diary-recorded symptom scores and questionnaire-recorded pain, diarrhea, and flushing. Conclusion: In addition to efficacy and quality of life benefits, symptom diaries from NETTER-1 demonstrated that treatment with 177Lu DOTATATE was associated with statistically significant reductions in abdominal pain, diarrhea, and flushing, constituting the core symptoms of patients with progressive midgut NETs, compared with high-dose octreotide LAR, supporting a beneficial effect of 177Lu DOTATATE on HRQoL.

Published
2021

10. EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

Author

Dillard, Christen, Kiyohara, Meagan, Mah, Vei, McDermott, Sean P, Bazzoun, Dana, Tsui, Jessica, Chan, Ann M, Haddad, Ghassan, Pellegrini, Matteo, Chang, Yu-Ling, Elshimali, Yahya, Wu, Yanyuan, Vadgama, Jaydutt V, Kim, Sara R, Goodglick, Lee, Law, Samuel M, Patel, Deven D, Dhawan, Puneet, O'Brien, Neil A, Gordon, Lynn K, Braun, Jonathan, Lazar, Gary, Wicha, Max S, and Wadehra, Madhuri

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Stem Cell Research - Nonembryonic - Human, Breast Cancer, Stem Cell Research, Stem Cell Research - Nonembryonic - Non-Human, Biotechnology, Cancer, 2.1 Biological and endogenous factors, Aetiology, Animals, Antibodies, Monoclonal, Apoptosis, Biomarkers, Tumor, Breast Neoplasms, Cell Proliferation, Epithelial-Mesenchymal Transition, Female, Gene Expression Regulation, Neoplastic, Humans, Membrane Glycoproteins, Mice, Mice, Inbred BALB C, Mice, Nude, Neoplasm Metastasis, Neoplastic Stem Cells, Tumor Cells, Cultured, Tumor Microenvironment, Xenograft Model Antitumor Assays, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Little is known about the role of epithelial membrane protein-2 (EMP2) in breast cancer development or progression. In this study, we tested the hypothesis that EMP2 may regulate the formation or self-renewal of breast cancer stem cells (BCSC) in the tumor microenvironment. In silico analysis of gene expression data demonstrated a correlation of EMP2 expression with known metastasis-related genes and markers of cancer stem cells (CSC) including aldehyde dehydrogenase (ALDH). In breast cancer cell lines, EMP2 overexpression increased and EMP2 knockdown decreased the proportion of stem-like cells as assessed by the expression of the CSC markers CD44+/CD24-, ALDH activity, or by tumor sphere formation. In vivo, upregulation of EMP2 promoted tumor growth, whereas knockdown reduced the ALDHhigh CSC population as well as retarded tumor growth. Mechanistically, EMP2 functionally regulated the response to hypoxia through the upregulation of HIF-1α, a transcription factor previously shown to regulate the self-renewal of ALDHhigh CSCs. Furthermore, in syngeneic mouse models and primary human tumor xenografts, mAbs directed against EMP2 effectively targeted CSCs, reducing the ALDH+ population and blocking their tumor-initiating capacity when implanted into secondary untreated mice. Collectively, our results show that EMP2 increases the proportion of tumor-initiating cells, providing a rationale for the continued development of EMP2-targeting agents.

Published
2020

11. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol

Author

Bhutani, Manoop S, Klapman, Jason B, Tuli, Richard, El-Haddad, Ghassan, Hoffe, Sarah, Wong, Franklin CL, Chasen, Beth, Fogelman, David R, Lo, Simon K, Nissen, Nicholas N, Hendifar, Andrew E, Varadhachary, Gauri, Katz, Matthew HG, Erwin, William D, Koay, Eugene J, Tamm, Eric P, Singh, Ben S, Mehta, Rutika, Wolff, Robert A, Soman, Ashish, Cazacu, Irina M, and Herman, Joseph M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Pancreatic Cancer, Digestive Diseases, Clinical Research, Orphan Drug, Rare Diseases, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Brachytherapy, EUS, chemotherapy, endoscopy, fine needle injection, intratumoral therapy, neoplasia, pancreatic cancer, phosphorus-32, radiotherapy
Abstract

Current treatment options for patients with unresectable locally advanced pancreatic cancer (LAPC) include chemotherapy alone or followed by chemoradiation or stereotactic body radiotherapy. However, the prognosis for these patients remains poor, with a median overall survival

Published
2020

15. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

Author

Loualidi, Ab, Colak, Abdurrahim, Bezuidenhout, Abraham, Abdool-Carrim, Abu, Azeddine, Addala, Beyers, Adriaan, Dees, Adriaan, Mohamed, Ahmed, Aksoy, Ahmet, Abiko, Akihiko, Watanabe, Akinori, Krichell, Alan, Fernandez, Alberto Alfredo, Tosetto, Alberto, Khotuntsov, Alexey, Oropallo, Alisha, Slocombe, Alison, Kelly, Allan, Clark, Amanda, Gad, Amr, Arouni, Amy, Schmidt, Andor, Berni, Andrea, Kleiban, Andres Javier, Machowski, Andrew, Kazakov, Andrey, Galvez, Angel, Lockman, Ann, Falanga, Anna, Chauhan, Anoop, Riera-Mestre, Antoni, Mazzone, Antonino, D'Angelo, Armando, Herdy, Artur, Kato, Atsushi, Salem, Ayman Abd Elhamid Ebrahim Mahmoud, Husin, Azlan, Erdelyi, Barbara, Jacobson, Barry, Amann-Vesti, Beatrice, Battaloglu, Bektas, Wilson, Benedicte, Cosmi, Benilde, Francois, Bergmann Jean, Toufek, Berremeli, Hunt, Beverley, Natha, Bhavesh, Mustafa, Bisher, Kho, Bonnie Chi Shan, Carine, Boulon, Zidel, Brian, Dominique, Brisot, Christophe, Brousse, Trimarco, Bruno, Luo, Canhua, Cuneo, Carlos Alberto, Diaz, Carlos Jerjes Sanchez, Schwencke, Carsten, Cader, Cas, Yavuz, Celal, Zaidman, Cesar Javier, Lunn, Charles, Wu, Chau-Chung, Toh, Cheng Hock, Chiang, Chern-En, Elisa, Chevrier, Hsia, Chien-Hsun, Huang, Chien-Lung, Kwok, Chi-Hang Kevin, Wu, Chih-Cheng, Huang, Chi-Hung, Ward, Chris, Opitz, Christian, Jeanneret-Gris, Christina, Ha, Chung Yin, Huang, Chun-Yao, Bidi, Claude Luyeye, Smith, Clifford, Brauer, Cornelia, Lodigiani, Corrado, Francis, Couturaud, Wu, Cynthia, Staub, Daniel, Theodoro, Daniel, Poli, Daniela, Acevedo, David - Riesco, Adler, David, Jimenez, David, Keeling, David, Scott, David, Imberti, Davide, Creagh, Desmond, Helene, Desmurs-Clavel, Hagemann, Dirk, Le Roux, Dirk, Skowasch, Dirk, Belenky, Dmitry, Dorokhov, Dmitry, Petrov, Dmitry, Zateyshchikov, Dmitry, Prisco, Domenico, Møller, Dorthe, Kucera, Dusan, Esheiba, Ehab M., Panchenko, Elizaveta, Dominique, Elkouri, Dogan, Emre, Kubat, Emre, Diaz, Enrique Diaz, Tse, Eric Wai Choi, Yeo, Erik, Hashas, Erman, Grochenig, Ernst, Tiraferri, Eros, Blessing, Erwin, Michèle, Escande Orthlieb, Usandizaga, Esther, Porreca, Ettore, Ferroni, Fabian, Nicolas, Falvo, Ayala-Paredes, Félix, Koura, Firas, Henry, Fitjerald, Cosmi, Franco, Erdkamp, Frans, Kamalov, Gadel, Dalmau, Garcia-Bragado, Damien, Garrigues, Klein, Garry, Shah, Gaurand, Hollanders, Geert, Merli, Geno, Plassmann, Georg, Platt, George, Poirier, Germain, Sokurenko, German, Haddad, Ghassan, Ali, Gholam, Agnelli, Giancarlo, Gan, Gin Gin, Kaye-Eddie, Grace, Le Gal, Gregoire, Allen, Gregory, Esperón, Guillermo Antonio Llamas, Jean-Paul, Guillot, Gerofke, Hagen, Elali, Hallah, Burianova, Hana, Ohler, Hans-Juergen, Wang, Haofu, Darius, Harald, Gogia, Harinder S., Striekwold, Harry, Gibbs, Harry, Hasanoglu, Hatice, Turker, Hatice, Franow, Hendrik, Bounameaux, Henri, De Raedt, Herbert, Schroe, Herman, ElDin, Hesham Salah, Zidan, Hesham, Nakamura, Hiroaki, Kim, Ho Young, Lawall, Holger, Zhu, Hong, Tian, Hongyan, Yhim, Ho-Young, ten Cate, Hugo, Hwang, Hun Gyu, Shim, Hyeok, Kim, Igor, Libov, Igor, Sonkin, Igor, Suchkov, Igor, Song, Ik-Chan, Kiris, Ilker, Staroverov, Ilya, Looi, Irene, De La Azuela Tenorio, Isabel M., Savas, Ismail, Gordeev, Ivan, Podpera, Ivo, Lee, Jae Hoon, Sathar, Jameela, Welker, James, Beyer-Westendorf, Jan, Kvasnicka, Jan, Vanwelden, Jan, Kim, JangYong, Svobodova, Jaromira, Gujral, Jaspal, Marino, Javier, Galvar, Javier Tristan, Kassis, Jeannine, Kuo, Jen-Yuan, Shih, Jhih-Yuan, Kwon, JiHyun, Joh, Jin Hyun, Park, Jin Hyun, Kim, Jin Seok, Yang, Jinghua, Krupicka, Jiri, Lastuvka, Jiri, Pumprla, Jiri, Vesely, Jiri, Souto, Joan Carlos, Correa, João Antônio, Duchateau, Johan, Fletcher, John Perry, del Toro, Jorge, Paez, Jorge Guillermo Chavez, Nielsen, Jørn, Filho, Jose Dalmo Araujo, Saraiva, Jose, Peromingo, Jose Antonio Diaz, Lara, Jose Gomez, Fedele, Jose Luis, Surinach, Jose Maria, Chacko, Joseph, Muntaner, Juan Antonio, Benitez, Juan Carlos Álvarez, Abril, Juan Moreno Hoyos, Humphrey, Julian, Bono, Julio, Kanda, Junji, Boondumrongsagoon, Juree, Yiu, Kai Hang, Chansung, Kanchana, Boomars, Karin, Burbury, Kate, Kondo, Katsuhiro, Karaarslan, Kemal, Takeuchi, Kensuke, Kroeger, Knut, Zrazhevskiy, Konstantin, Svatopluk, Koscál, Shyu, Kou-Gi, Vandenbosch, Kristel, Chang, Kuan-Cheng, Chiu, Kuan-Ming, Jean-Manuel, Kubina, Wern, Kwan Jing, Ueng, Kwo-Chang, Norasetthada, Lalita, Binet, Laure, Chew, Lee Ping, Zhang, Lei, Cristina, Leone Maria, Tick, Lidwine, Schiavi, Lilia Beatriz, Wong, Lily Lee Lee, Borges, Lohana, Botha, Louis, Capiau, Luc, Timmermans, Luc, López, Luciano Eduardo, Ria, Luigi, Blasco, Luis Manuel Hernandez, Guzman, Luis Alberto, Cervera, Luis Flota, Isabelle, Mahe, Bosch, Manuel Monreal, de los Rios Ibarra, Manuel, Fernandez, Manuel Núñez, Carrier, Marc, Barrionuevo, Marcelo Raul, Gamba, Marco Antonio Alcocer, Cattaneo, Marco, Moia, Marco, Bowers, Margaret, Chetanachan, Mariam, Berli, Mario Alberto, Fixley, Mark, Faghih, Markus, Stuecker, Markus, Schul, Marlin, Banyai, Martin, Koretzky, Martin, Myriam, Martin, Gaffney, Mary Elizabeth, Hirano, Masao, Kanemoto, Masashi, Nakamura, Mashio, Tahar, Mersel, Emmanuel, Messas, Kovacs, Michael, Leahy, Michael, Levy, Michael, Munch, Michael, Olsen, Michael, De Pauw, Michel, Gustin, Michel, Van Betsbrugge, Michiel, Boyarkin, Mikhail, Homza, Miroslav, Koto, Modise, Abdool-Gaffar, Mohamed, Nagib, Mohamed Ayman Fakhry, El-Dessoki, Mohamed, Khan, Mohamed, Mohamed, Monniaty, Kim, Moo Hyun, Lee, Moon-Hee, Soliman, Mosaad, Ahmed, Mostafa Shawky, el Bary, Mostafa Soliman Abd, Moustafa, Moustafa A., Hameed, Muhammad, Kanko, Muhip, Majumder, Mujibur, Zubareva, Nadezhda, Mumoli, Nicola, Abdullah, Nik Azim Nik, Makruasi, Nisa, Paruk, Nishen, Kanitsap, Nonglak, Duda, Norberto, Nordin, Nordiana, Nyvad, Ole, Barbarash, Olga, Gurbuz, Orcun, Vilamajo, Oscar Gomez, Flores, Oscar Nandayapa, Gur, Ozcan, Oto, Oztekin, Marchena, Pablo Javier, Angchaisuksiri, Pantep, Carroll, Patrick, Lang, Pavel, MacCallum, Peter, von Bilderling, Peter Baron, Blombery, Peter, Verhamme, Peter, Jansky, Petr, Bernadette, Peuch, De Vleeschauwer, Philippe, Hainaut, Philippe, Ferrini, Piera Maria, Iamsai, Piriyaporn, Christian, Ponchaux, Viboonjuntra, Pongtep, Rojnuckarin, Ponlapat, Ho, Prahlad, Mutirangura, Pramook, Wells, Rachel, Martinez, Rafael, Miranda, Raimundo Tirado, Kroening, Ralf, Ratsela, Rapule, Reyes, Raquel Lopez, de Leon, Raul Franco Diaz, Wong, Raymond Siu Ming, Alikhan, Raz, Jerwan-Keim, Reinhold, Otero, Remedios, Murena-Schmidt, Renate, Canevascini, Reto, Ferkl, Richard, White, Richard, Van Herreweghe, Rika, Santoro, Rita, Klamroth, Robert, Mendes, Robert, Prosecky, Robert, Cappelli, Roberto, Spacek, Rudolf, Singh, Rupesh, Griffin, Sam, Na, Sang Hoon, Chunilal, Sanjeev, Middeldorp, Saskia, Nakazawa, Satoshi, Schellong, Sebastian, Toh, See Guan, Christophe, Seinturier, Isbir, Selim, Raymundo, Selma, Ting, Seng Kiat, Motte, Serge, Aktogu, Serir Ozkan, Donders, Servaas, Cha, Seung Ick, Nam, Seung-Hyun, Marie-Antoinette, Sevestre-Pietri, Maasdorp, Shaun, Sun, Shenghua, Wang, Shenming, Essameldin, Sherif Mohamed, Sholkamy, Sherif Mohamed, Kuki, Shintaro, Goto, Shinya, Yoshida, Shuichi, Matsuoka, Shunzo, McRae, Simon, Watt, Simon, Patanasing, Siriwimon, Jean-Léopold, Siwe-Nana, Wongkhantee, Somchai, Bang, Soo-Mee, Testa, Sophie, Zemek, Stanislav, Behrens, Steffen, Dominique, Stephan, Mellor, Stuart, Singh, Suaran Singh Gurcharan, Datta, Sudip, Chayangsu, Sunee, Solymoss, Susan, Everington, Tamara, Abdel-Azim, Tarek Ahmed Adel, Suwanban, Tawatchai, Adademir, Taylan, Hart, Terence, Béatrice, Terriat, Luvhengo, Thifhelimbilu, Horacek, Thomas, Zeller, Thomas, Boussy, Tim, Reynolds, Tim, Biss, Tina, Chao, Ting-Hsing, Casabella, Tomas Smith, Onodera, Tomoya, Numbenjapon, Tontanai, Gerdes, Victor, Cech, Vladimir, Krasavin, Vladimir, Tolstikhin, Vladimir, Bax, W.A., Malek, Wagih Fawzy Abdel, Ho, Wai Khoon, Ageno, Walter, Pharr, Walter, Jiang, Weihong, Lin, Wei-Hsiang, Zhang, Weihua, Tseng, Wei-Kung, Lai, Wen-Ter, De Backer, Wilfried, Haverkamp, Wilhelm, Yoshida, Winston, Korte, Wolfgang, Choi, Won Il, Kim, Yang-Ki, Tanabe, Yasuhiro, Ohnuma, Yasushi, Mun, Yeung-Chul, Balthazar, Yohan, Park, Yong, Shibata, Yoshisato, Burov, Yuriy, Subbotin, Yuriy, Coufal, Zdenek, Yang, Zhenwen, Jing, Zhicheng, Yang, Zhongqi, Turpie, Alexander G.G., Farjat, Alfredo E., Haas, Sylvia, Weitz, Jeffrey I., Goldhaber, Samuel Z., Kayani, Gloria, Lopes, Renato D., Tse, Eric, Muntaner, Juan, Prandoni, Paolo, Maheshwari, Uma, and Kakkar, Ajay K.

Published
2023
Full Text
View/download PDF

16. Hepatic Radioembolization

Author

Ramdhani, K., primary, Lam, Marnix G.E.H., additional, Braat, Arthur J.A.T., additional, Smits, Maarten L.J., additional, and El-Haddad, Ghassan, additional

Published
2024
Full Text
View/download PDF

17. First-in-human study of 225actinium mti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM).

Author

Khushalani, Nikhil I., primary, El-Haddad, Ghassan, additional, Gage, Kenneth L., additional, Budzevich, Mikalai, additional, Schell, Michael J, additional, Moros, Eduardo G, additional, Tichacek, Christopher, additional, Gibbons, William R, additional, Rogers, Rebecca E, additional, Nickels, Michael L, additional, Tetteh, Leticia, additional, Eroglu, Zeynep, additional, Karapetyan, Lilit, additional, Brohl, Andrew Scott, additional, Markowitz, Joseph, additional, Tarhini, Ahmad A., additional, Hayes, Karen, additional, Hazlehurst, Lori, additional, McLaughlin, Mark, additional, and Morse, David L, additional

Published
2024
Full Text
View/download PDF

21. Hepatic Radioembolization: A Multistep Theragnostic Procedure

Author

Researchgr. Nucleaire Geneeskunde, Cancer, MS Radiologie, Ramdhani, K., Lam, Marnix G.E.H., Braat, Arthur J.A.T., Smits, Maarten L.J., El-Haddad, Ghassan, Researchgr. Nucleaire Geneeskunde, Cancer, MS Radiologie, Ramdhani, K., Lam, Marnix G.E.H., Braat, Arthur J.A.T., Smits, Maarten L.J., and El-Haddad, Ghassan

Published
2024

23. Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors.

Author

Alayli, Adam, Ngo, Hoang, Sikaria, Dhiraj, Ahmed, Altan, Salloum, Elias, Strosberg, Jonathan R., Al-Toubah, Taymeyah E., Kis, Bela, Haider, Mintallah, and El-Haddad, Ghassan

Subjects
RADIOISOTOPE therapy, PATIENT safety, HEPATOTOXICOLOGY, STATISTICAL significance, THERAPEUTIC embolization, RETROSPECTIVE studies, TREATMENT duration, CANCER patients, METASTASIS, KAPLAN-Meier estimator, NEUROENDOCRINE tumors, DRUG efficacy, SOCIODEMOGRAPHIC factors, PROGRESSION-free survival, CELL receptors, TIME, EVALUATION
Abstract

Simple Summary: Peptide receptor radionuclide therapy using 177Lu-DOTATATE is a standard therapy for patients with metastatic neuroendocrine tumors. Many patients with liver-dominant disease undergo liver embolization as an earlier line of treatment. It is unclear whether prior embolization impacts the safety and efficacy of subsequent 177Lu-DOTATATE treatment. We analyzed 171 patients who underwent treatment with 177Lu-DOTATATE, among whom 61 underwent prior embolization. There was no significant difference in serious liver toxicity or radiographic progression of liver tumors between the group that had undergone prior embolization and the group that had not. The conclusion is that peptide receptor radionuclide therapy with 177Lu-DOTATATE in patients who had prior liver embolization is both safe and effective. Rationale: Evaluating the long-term safety and efficacy of peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumors (mNETs) who have undergone prior bland hepatic transarterial embolization (TAE). Methods: Retrospective review of mNET patients who received PRRT with 177Lu-DOTATATE between 4/2018 and 02/2022 with and without prior TAE. The most recent clinical, imaging, and laboratory findings, including hepatic Common Terminology Criteria for Adverse Events v5.0, were compared to pre-PRRT. Results: 171 patients (95 M, 76 F, median age = 66) with mNET of different primary sites (9 foregut, 100 midgut, 9 hindgut, 44 pancreas, 9 unknown) received at least 1 cycle of PRRT with at least 6 months of follow-up, 110 of whom were embolization-naïve and 61 who had prior TAE. The median follow up was 22 months (range: 6–43). Patients with prior TAE had higher liver tumor burden on average than patients without prior TAE; however, the difference was not statistically significant (p = 0.06). There was no significant difference in the rates of G3 or G4 hepatotoxicity (p = 0.548 and p = 0.999, respectively) in patients who underwent prior TAE and those who were TAE-naïve. The hepatic progression-free survival was 22.9 months in TAE-naïve patients and 25.7, 20.2, and 12.8 months in patients with 1, 2, and 3 prior TAE treatments, respectively. Conclusion: Peptide receptor radionuclide therapy following transarterial bland embolization for mNET is safe and effective. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients

Author

Haas, Sylvia, Ageno, Walter, Weitz, Jeffrey I., Goldhaber, Samuel Z., Turpie, Alexander G.G., Goto, Shinya, Angchaisuksiri, Pantep, Dalsgaard Nielsen, Joern, Kayani, Gloria, Zaghdoun, Audrey, Farjat, Alfredo E., Schellong, Sebastian, Bounameaux, Henri, Mantovani, Lorenzo G., Prandoni, Paolo, Kakkar, Ajay K., Loualidi, Ab, Colak, Abdurrahim, Bezuidenhout, Abraham, Abdool‐Carrim, Abu, Azeddine, Addala, Beyers, Adriaan, Dees, Adriaan, Mohamed, Ahmed, Aksoy, Ahmet, Abiko, Akihiko, Watanabe, Akinori, Krichell, Alan, Fernandez, Alberto Alfredo, Tosetto, Alberto, Khotuntsov, Alexey, Oropallo, Alisha, Slocombe, Alison, Kelly, Allan, Clark, Amanda, Gad, Amr, Arouni, Amy, Schmidt, Andor, Berni, Andrea, Kleiban, Andres Javier, Machowski, Andrew, Kazakov, Andrey, Galvez, Angel, Lockman, Ann, Falanga, Anna, Chauhan, Anoop, Riera‐Mestre, Antoni, Mazzone, Antonino, D'Angelo, Armando, Herdy, Artur, Kato, Atsushi, Ebrahim, Ayman Abd Elhamid, Salem, Mahmoud, Husin, Azlan, Erdelyi, Barbara, Jacobson, Barry, Amann‐Vesti, Beatrice, Battaloglu, Bektas, Wilson, Benedicte, Cosmi, Benilde, Francois, Bergmann Jean, Toufek, Berremeli, Hunt, Beverley, Natha, Bhavesh, Mustafa, Bisher, Kho, Bonnie Chi Shan, Carine, Boulon, Zidel, Brian, Dominique, Brisot, Christophe, Brousse, Trimarco, Bruno, Luo, Canhua, Alberto Cuneo, Carlos, Sanchez Diaz, Carlos Jerjes, Schwencke, Carsten, Cader, Cas, Yavuz, Celal, Javier Zaidman, Cesar, Lunn, Charles, Wu, Chau‐Chung, Toh, Cheng Hock, Chiang, Chern‐En, Elisa, Chevrier, Hsia, Chien‐Hsun, Huang, Chien‐Lung, Kwok, Chi‐Hang Kevin, Wu, Chih‐Cheng, Huang, Chi‐Hung, Ward, Chris, Opitz, Christian, Jeanneret‐Gris, Christina, Ha, Chung Yin, Huang, Chun‐Yao, Bidi, Claude Luyeye, Smith, Clifford, Brauer, Cornelia, Lodigiani, Corrado, Francis, Couturaud, Wu, Cynthia, Staub, Daniel, Theodoro, Daniel, Poli, Daniela, Acevedo, Riesco, Adler, David, Jimenez, David, Keeling, David, Scott, David, Imberti, Davide, Creagh, Desmond, Helene, Desmurs‐Clavel, Hagemann, Dirk, Le Roux, Dirk, Skowasch, Dirk, Belenky, Dmitry, Dorokhov, Dmitry, Petrov, Dmitry, Zateyshchikov, Dmitry, Prisco, Domenico, Møller, Dorthe, Kucera, Dusan, Esheiba, Ehab M., Panchenko, Elizaveta, Dominique, Elkouri, Dogan, Emre, Kubat, Emre, Diaz Diaz, Enrique, Tse, Eric Wai Choi, Yeo, Erik, Hashas, Erman, Grochenig, Ernst, Tiraferri, Eros, Blessing, Erwin, Michèle, Escande Orthlieb, Usandizaga, Esther, Porreca, Ettore, Ferroni, Fabian, Nicolas, Falvo, Ayala‐Paredes, Félix, Koura, Firas, Henry, Fitjerald, Cosmi, Franco, Erdkamp, Frans, Kamalov, Gadel, Dalmau, Garcia‐Bragado, Damien, Garrigues, Klein, Garry, Shah, Gaurand, Hollanders, Geert, Merli, Geno, Plassmann, Georg, Platt, George, Poirier, Germain, Sokurenko, German, Haddad, Ghassan, Ali, Gholam, Agnelli, Giancarlo, Gan, Gin Gin, Kaye‐Eddie, Grace, Le Gal, Gregoire, Allen, Gregory, Llamas Esperón, Guillermo Antonio, Jean‐Paul, Guillot, Gerofke, Hagen, Elali, Hallah, Burianova, Hana, Ohler, Hans‐Juergen, Wang, Haofu, Darius, Harald, Gogia, Harinder S., Striekwold, Harry, Gibbs, Harry, Hasanoglu, Hatice, Turker, Hatice, Franow, Hendrik, De Raedt, Herbert, Schroe, Herman, ElDin, Hesham Salah, Zidan, Hesham, Nakamura, Hiroaki, Kim, Ho Young, Lawall, Holger, Zhu, Hong, Tian, Hongyan, Yhim, Ho‐Young, ten Cate, Hugo, Hwang, Hun Gyu, Shim, Hyeok, Kim, Igor, Libov, Igor, Sonkin, Igor, Suchkov, Igor, Song, Ik‐Chan, Kiris, Ilker, Staroverov, Ilya, Looi, Irene, De La Azuela Tenorio, Isabel M, Savas, Ismail, Gordeev, Ivan, Podpera, Ivo, Lee, Jae Hoon, Sathar, Jameela, Welker, James, Beyer‐Westendorf, Jan, Kvasnicka, Jan, Vanwelden, Jan, Kim, JangYong, Svobodova, Jaromira, Gujral, Jaspal, Marino, Javier, Galvar, Javier Tristan, Kassis, Jeannine, Kuo, Jen‐Yuan, Shih, Jhih‐Yuan, Kwon, JiHyun, Joh, Jin Hyun, Park, Jin Hyun, Kim, Jin Seok, Yang, Jinghua, Krupicka, Jiri, Lastuvka, Jiri, Pumprla, Jiri, Vesely, Jiri, Carlos Souto, Joan, Antônio Correa, João, Duchateau, Johan, Fletcher, John Perry, del Toro, Jorge, Chavez Paez, Jorge Guillermo, Araujo Filho, Jose Dalmo, Saraiva, Jose, Diaz Peromingo, Jose Antonio, Gomez Lara, Jose, Luis Fedele, Jose, Maria Surinach, Jose, Chacko, Joseph, Antonio Muntaner, Juan, Álvarez Benitez, Juan Carlos, Hoyos Abril, Juan Moreno, Humphrey, Julian, Bono, Julio, Kanda, Junji, Boondumrongsagoon, Juree, Yiu, Kai Hang, Chansung, Kanchana, Boomars, Karin, Burbury, Kate, Kondo, Katsuhiro, Karaarslan, Kemal, Takeuchi, Kensuke, Kroeger, Knut, Zrazhevskiy, Konstantin, Svatopluk, Koscál, Shyu, Kou‐Gi, Vandenbosch, Kristel, Chang, Kuan‐Cheng, Chiu, Kuan‐Ming, Jean‐Manuel, Kubina, Wern, Kwan Jing, Ueng, Kwo‐Chang, Norasetthada, Lalita, Binet, Laure, Chew, Lee Ping, Zhang, Lei, Cristina, Leone Maria, Tick, Lidwine, Beatriz Schiavi, Lilia, Wong, Lily Lee Lee, Borges, Lohana, Botha, Louis, Capiau, Luc, Timmermans, Luc, Eduardo López, Luciano, Ria, Luigi, Hernandez Blasco, Luis Manuel, Guzman, Luis Alberto, Flota Cervera, Luis, Isabelle, Mahe, Monreal Bosch, Manuel, de los Rios Ibarra, Manuel, Núñez Fernandez, Manuel, Carrier, Marc, Raul Barrionuevo, Marcelo, Alcocer Gamba, Marco Antonio, Cattaneo, Marco, Moia, Marco, Bowers, Margaret, Chetanachan, Mariam, Berli, Mario Alberto, Fixley, Mark, Faghih, Markus, Stuecker, Markus, Schul, Marlin, Banyai, Martin, Koretzky, Martin, Myriam, Martin, Gaffney, Mary Elizabeth, Hirano, Masao, Kanemoto, Masashi, Nakamura, Mashio, Tahar, Mersel, Emmanuel, Messas, Kovacs, Michael, Leahy, Michael, Levy, Michael, Munch, Michael, Olsen, Michael, De Pauw, Michel, Gustin, Michel, Van Betsbrugge, Michiel, Boyarkin, Mikhail, Homza, Miroslav, Koto, Modise, Abdool‐Gaffar, Mohamed, Nagib, Mohamed Ayman Fakhry, El‐Dessoki, Mohamed, Khan, Mohamed, Mohamed, Monniaty, Kim, Moo Hyun, Lee, Moon‐Hee, Soliman, Mosaad, Ahmed, Mostafa Shawky, el Bary, Mostafa Soliman Abd, Moustafa, Moustafa A., Hameed, Muhammad, Kanko, Muhip, Majumder, Mujibur, Zubareva, Nadezhda, Mumoli, Nicola, Abdullah, Nik Azim Nik, Makruasi, Nisa, Paruk, Nishen, Kanitsap, Nonglak, Duda, Norberto, Nordin, Nordiana, Nyvad, Ole, Barbarash, Olga, Gurbuz, Orcun, Vilamajo, Oscar Gomez, Nandayapa Flores, Oscar, Gur, Ozcan, Oto, Oztekin, Javier Marchena, Pablo, Carroll, Patrick, Lang, Pavel, MacCallum, Peter, von Bilderling, Peter Baron, Blombery, Peter, Verhamme, Peter, Jansky, Petr, Bernadette, Peuch, De Vleeschauwer, Philippe, Hainaut, Philippe, Ferrini, Piera Maria, Iamsai, Piriyaporn, Christian, Ponchaux, Viboonjuntra, Pongtep, Rojnuckarin, Ponlapat, Ho, Prahlad, Mutirangura, Pramook, Wells, Rachel, Martinez, Rafael, Miranda, Raimundo Tirado, Kroening, Ralf, Ratsela, Rapule, Reyes, Raquel Lopez, Diaz de Leon, Raul Franco, Wong, Raymond Siu Ming, Alikhan, Raz, Jerwan‐Keim, Reinhold, Otero, Remedios, Murena‐Schmidt, Renate, Canevascini, Reto, Ferkl, Richard, White, Richard, Van Herreweghe, Rika, Santoro, Rita, Klamroth, Robert, Mendes, Robert, Prosecky, Robert, Cappelli, Roberto, Spacek, Rudolf, Singh, Rupesh, Griffin, Sam, Na, Sang Hoon, Chunilal, Sanjeev, Middeldorp, Saskia, Nakazawa, Satoshi, Toh, See Guan, Christophe, Seinturier, Isbir, Selim, Raymundo, Selma, Ting, Seng Kiat, Motte, Serge, Aktogu, Serir Ozkan, Donders, Servaas, Cha, Seung Ick, Nam, Seung‐Hyun, Marie‐Antoinette, Sevestre‐Pietri, Maasdorp, Shaun, Sun, Shenghua, Wang, Shenming, Essameldin, Sherif Mohamed, Sholkamy, Sherif Mohamed, Kuki, Shintaro, Yoshida, Shuichi, Matsuoka, Shunzo, McRae, Simon, Watt, Simon, Patanasing, Siriwimon, Jean‐Léopold, Siwe‐Nana, Wongkhantee, Somchai, Bang, Soo‐Mee, Testa, Sophie, Zemek, Stanislav, Behrens, Steffen, Dominique, Stephan, Mellor, Stuart, Singh, Suaran Singh Gurcharan, Datta, Sudip, Chayangsu, Sunee, Solymoss, Susan, Everington, Tamara, Abdel‐Azim, Tarek Ahmed Adel, Suwanban, Tawatchai, Adademir, Taylan, Hart, Terence, Béatrice, Terriat, Luvhengo, Thifhelimbilu, Horacek, Thomas, Zeller, Thomas, Boussy, Tim, Reynolds, Tim, Biss, Tina, Chao, Ting‐Hsing, Casabella, Tomas Smith, Onodera, Tomoya, Numbenjapon, Tontanai, Gerdes, Victor, Cech, Vladimir, Krasavin, Vladimir, Tolstikhin, Vladimir, Bax, W.A., Malek, Wagih Fawzy Abdel, Ho, Wai Khoon, Pharr, Walter, Jiang, Weihong, Lin, Wei‐Hsiang, Zhang, Weihua, Tseng, Wei‐Kung, Lai, Wen‐Ter, De Backer, Wilfried, Haverkamp, Wilhelm, Yoshida, Winston, Korte, Wolfgang, Choi, Won II, Kim, Yang‐Ki, Tanabe, Yasuhiro, Ohnuma, Yasushi, Mun, Yeung‐Chul, Balthazar, Yohan, Park, Yong, Shibata, Yoshisato, Burov, Yuriy, Subbotin, Yuriy, Coufal, Zdenek, Yang, Zhenwen, Jing, Zhicheng, and Yang, Zhongqi

Published
2019
Full Text
View/download PDF

29. 629-D The anti-tumor activity of IFNβ and membrane-stable CD40L expressing oncolytic virus MEM-288 in NSCLC patients is associated with modulation of the tumor microenvironment and systemic immune response

Author

Saltos, Andreas N, primary, Arrowood, Christy, additional, Beasley, Georgia M, additional, Ronald, James, additional, El-Haddad, Ghassan, additional, Gray, Jhanelle E, additional, Pellini, Bruna, additional, Tanvetyanon, Tawee, additional, Guerra-Guevara, Luiziane, additional, Khan, Uzma, additional, Wolf, Steven, additional, Gu, Lin, additional, Wang, Xiaofei, additional, Zheng, Hong, additional, Foresman, Dana, additional, Yu, Xiaoqing, additional, Cantwell, Mark J, additional, Antonia, Scott J, additional, Beg, Amer A, additional, and Ready, Neal E, additional

Published
2023
Full Text
View/download PDF

31. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study

Author

Gangi, Alexandra, Shah, Jehan, Hatfield, Nathan, Smith, Johnna, Sweeney, Jennifer, Choi, Junsung, El-Haddad, Ghassan, Biebel, Benjamin, Parikh, Nainesh, Arslan, Bulent, Hoffe, Sarah E., Frakes, Jessica M., Springett, Gregory M., Anaya, Daniel A., Malafa, Mokenge, Chen, Dung-Tsa, Chen, Yunyun, Kim, Richard D., Shridhar, Ravi, and Kis, Bela

Published
2018
Full Text
View/download PDF

38. A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).

Author

Saltos, Andreas Nicholas, primary, Arrowood, Christy, additional, Beasley, Georgia, additional, Ronald, James, additional, El-Haddad, Ghassan, additional, Guerra-Guevara, Luiziane, additional, Khan, Uzma, additional, Wolf, Steven, additional, Gu, Lin, additional, Wang, Xiaofei F., additional, Foresman, Dana, additional, Yu, Xiaoqing, additional, Cantwell, Mark J., additional, Antonia, Scott Joseph, additional, Beg, Amer A, additional, and Ready, Neal E., additional

Published
2023
Full Text
View/download PDF

39. Abstract CT103: A phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity

Author

Saltos, Andreas N., primary, Arrowood, Christy, additional, Beasley, Georgia, additional, Ronald, James, additional, El-Haddad, Ghassan, additional, Khan, Uzma, additional, Guerra-Guevara, Luiziane, additional, Wolf, Steven, additional, Gu, Lin, additional, Wang, Xiaofei F., additional, Foresman, Dana, additional, Yu, Xiaoqing, additional, Cantwell, Mark J., additional, Antonia, Scott J., additional, Beg, Amer A., additional, and Ready, Neal E., additional

Published
2023
Full Text
View/download PDF

40. Figure S3 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

Author

Dillard, Christen, primary, Kiyohara, Meagan, primary, Mah, Vei, primary, McDermott, Sean P., primary, Bazzoun, Dana, primary, Tsui, Jessica, primary, Chan, Ann M., primary, Haddad, Ghassan, primary, Pellegrini, Matteo, primary, Chang, Yu-Ling, primary, Elshimali, Yahya, primary, Wu, Yanyuan, primary, Vadgama, Jaydutt V., primary, Kim, Sara R., primary, Goodglick, Lee, primary, Law, Samuel M., primary, Patel, Deven D., primary, Dhawan, Puneet, primary, O'Brien, Neil A., primary, Gordon, Lynn K., primary, Braun, Jonathan, primary, Lazar, Gary, primary, Wicha, Max S., primary, and Wadehra, Madhuri, primary

Published
2023
Full Text
View/download PDF

41. Supplemental Data from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

Author

Dillard, Christen, primary, Kiyohara, Meagan, primary, Mah, Vei, primary, McDermott, Sean P., primary, Bazzoun, Dana, primary, Tsui, Jessica, primary, Chan, Ann M., primary, Haddad, Ghassan, primary, Pellegrini, Matteo, primary, Chang, Yu-Ling, primary, Elshimali, Yahya, primary, Wu, Yanyuan, primary, Vadgama, Jaydutt V., primary, Kim, Sara R., primary, Goodglick, Lee, primary, Law, Samuel M., primary, Patel, Deven D., primary, Dhawan, Puneet, primary, O'Brien, Neil A., primary, Gordon, Lynn K., primary, Braun, Jonathan, primary, Lazar, Gary, primary, Wicha, Max S., primary, and Wadehra, Madhuri, primary

Published
2023
Full Text
View/download PDF

42. Table S4 from EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells

Author

Dillard, Christen, primary, Kiyohara, Meagan, primary, Mah, Vei, primary, McDermott, Sean P., primary, Bazzoun, Dana, primary, Tsui, Jessica, primary, Chan, Ann M., primary, Haddad, Ghassan, primary, Pellegrini, Matteo, primary, Chang, Yu-Ling, primary, Elshimali, Yahya, primary, Wu, Yanyuan, primary, Vadgama, Jaydutt V., primary, Kim, Sara R., primary, Goodglick, Lee, primary, Law, Samuel M., primary, Patel, Deven D., primary, Dhawan, Puneet, primary, O'Brien, Neil A., primary, Gordon, Lynn K., primary, Braun, Jonathan, primary, Lazar, Gary, primary, Wicha, Max S., primary, and Wadehra, Madhuri, primary

Published
2023
Full Text
View/download PDF

43. Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer.

Author

Gudenkauf, Lisa M, Gudenkauf, Lisa M, Chavez, Melody N, Maconi, Melinda Leigh, Geiss, Carley, Seyedroudbari, Ameen, Thin, Pan, Hoogland, Aasha I, Nguyen, Kathleen, Murthy, Vishnu, Armstrong, Wesley R, Komrokji, Khaled, Oswald, Laura B, Jim, Heather SL, El-Haddad, Ghassan, Fendler, Wolfgang P, Herrmann, Ken, Cella, David, Czernin, Johannes, Hofman, Michael S, Dicker, Adam P, Calais, Jeremie, Tagawa, Scott T, Gonzalez, Brian D, Gudenkauf, Lisa M, Gudenkauf, Lisa M, Chavez, Melody N, Maconi, Melinda Leigh, Geiss, Carley, Seyedroudbari, Ameen, Thin, Pan, Hoogland, Aasha I, Nguyen, Kathleen, Murthy, Vishnu, Armstrong, Wesley R, Komrokji, Khaled, Oswald, Laura B, Jim, Heather SL, El-Haddad, Ghassan, Fendler, Wolfgang P, Herrmann, Ken, Cella, David, Czernin, Johannes, Hofman, Michael S, Dicker, Adam P, Calais, Jeremie, Tagawa, Scott T, and Gonzalez, Brian D

Abstract

The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first 177Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. Methods: We identified relevant symptoms and toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) with patient input. Results: This multistep process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The FACT-RNT is a new standardized tool to monitor relevant symptoms and toxicities among PC patients in RNT trials and real-world settings.

Published
2023

46. Developing a novel patient-reported outcome measure for patients with prostate cancer receiving radionuclide therapy: The FACT-RNT.

Author

Gudenkauf, Lisa M., primary, Chavez, Melody, additional, Maconi, Melinda, additional, Geiss, Carley, additional, Seyedroudbari, Ameen, additional, Thin, Pan, additional, Hoogland, Aasha, additional, Nguyen, Kathleen, additional, Oswald, Laura B., additional, Jim, Heather S.L., additional, El-Haddad, Ghassan, additional, Fendler, Wolfgang Peter, additional, Herrmann, Ken, additional, Cella, David, additional, Czernin, Johannes, additional, Hofman, Michael S, additional, Dicker, Adam P., additional, Calais, Jeremie, additional, Tagawa, Scott T., additional, and Gonzalez, Brian D., additional

Published
2023
Full Text
View/download PDF

47. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE

Author

Turpie, Alexander G.G., primary, Farjat, Alfredo E., additional, Haas, Sylvia, additional, Ageno, Walter, additional, Weitz, Jeffrey I., additional, Goldhaber, Samuel Z., additional, Goto, Shinya, additional, Angchaisuksiri, Pantep, additional, Kayani, Gloria, additional, Lopes, Renato D., additional, Chiang, Chern-En, additional, Gibbs, Harry, additional, Tse, Eric, additional, Verhamme, Peter, additional, ten Cate, Hugo, additional, Muntaner, Juan, additional, Schellong, Sebastian, additional, Bounameaux, Henri, additional, Prandoni, Paolo, additional, Maheshwari, Uma, additional, Kakkar, Ajay K., additional, Loualidi, Ab, additional, Colak, Abdurrahim, additional, Bezuidenhout, Abraham, additional, Abdool-Carrim, Abu, additional, Azeddine, Addala, additional, Beyers, Adriaan, additional, Dees, Adriaan, additional, Mohamed, Ahmed, additional, Aksoy, Ahmet, additional, Abiko, Akihiko, additional, Watanabe, Akinori, additional, Krichell, Alan, additional, Fernandez, Alberto Alfredo, additional, Tosetto, Alberto, additional, Khotuntsov, Alexey, additional, Oropallo, Alisha, additional, Slocombe, Alison, additional, Kelly, Allan, additional, Clark, Amanda, additional, Gad, Amr, additional, Arouni, Amy, additional, Schmidt, Andor, additional, Berni, Andrea, additional, Kleiban, Andres Javier, additional, Machowski, Andrew, additional, Kazakov, Andrey, additional, Galvez, Angel, additional, Lockman, Ann, additional, Falanga, Anna, additional, Chauhan, Anoop, additional, Riera-Mestre, Antoni, additional, Mazzone, Antonino, additional, D'Angelo, Armando, additional, Herdy, Artur, additional, Kato, Atsushi, additional, Salem, Ayman Abd Elhamid Ebrahim Mahmoud, additional, Husin, Azlan, additional, Erdelyi, Barbara, additional, Jacobson, Barry, additional, Amann-Vesti, Beatrice, additional, Battaloglu, Bektas, additional, Wilson, Benedicte, additional, Cosmi, Benilde, additional, Francois, Bergmann Jean, additional, Toufek, Berremeli, additional, Hunt, Beverley, additional, Natha, Bhavesh, additional, Mustafa, Bisher, additional, Kho, Bonnie Chi Shan, additional, Carine, Boulon, additional, Zidel, Brian, additional, Dominique, Brisot, additional, Christophe, Brousse, additional, Trimarco, Bruno, additional, Luo, Canhua, additional, Cuneo, Carlos Alberto, additional, Diaz, Carlos Jerjes Sanchez, additional, Schwencke, Carsten, additional, Cader, Cas, additional, Yavuz, Celal, additional, Zaidman, Cesar Javier, additional, Lunn, Charles, additional, Wu, Chau-Chung, additional, Toh, Cheng Hock, additional, Elisa, Chevrier, additional, Hsia, Chien-Hsun, additional, Huang, Chien-Lung, additional, Kwok, Chi-Hang Kevin, additional, Wu, Chih-Cheng, additional, Huang, Chi-Hung, additional, Ward, Chris, additional, Opitz, Christian, additional, Jeanneret-Gris, Christina, additional, Ha, Chung Yin, additional, Huang, Chun-Yao, additional, Bidi, Claude Luyeye, additional, Smith, Clifford, additional, Brauer, Cornelia, additional, Lodigiani, Corrado, additional, Francis, Couturaud, additional, Wu, Cynthia, additional, Staub, Daniel, additional, Theodoro, Daniel, additional, Poli, Daniela, additional, Acevedo, David - Riesco, additional, Adler, David, additional, Jimenez, David, additional, Keeling, David, additional, Scott, David, additional, Imberti, Davide, additional, Creagh, Desmond, additional, Helene, Desmurs-Clavel, additional, Hagemann, Dirk, additional, Le Roux, Dirk, additional, Skowasch, Dirk, additional, Belenky, Dmitry, additional, Dorokhov, Dmitry, additional, Petrov, Dmitry, additional, Zateyshchikov, Dmitry, additional, Prisco, Domenico, additional, Møller, Dorthe, additional, Kucera, Dusan, additional, Esheiba, Ehab M., additional, Panchenko, Elizaveta, additional, Dominique, Elkouri, additional, Dogan, Emre, additional, Kubat, Emre, additional, Diaz, Enrique Diaz, additional, Tse, Eric Wai Choi, additional, Yeo, Erik, additional, Hashas, Erman, additional, Grochenig, Ernst, additional, Tiraferri, Eros, additional, Blessing, Erwin, additional, Michèle, Escande Orthlieb, additional, Usandizaga, Esther, additional, Porreca, Ettore, additional, Ferroni, Fabian, additional, Nicolas, Falvo, additional, Ayala-Paredes, Félix, additional, Koura, Firas, additional, Henry, Fitjerald, additional, Cosmi, Franco, additional, Erdkamp, Frans, additional, Kamalov, Gadel, additional, Dalmau, Garcia-Bragado, additional, Damien, Garrigues, additional, Klein, Garry, additional, Shah, Gaurand, additional, Hollanders, Geert, additional, Merli, Geno, additional, Plassmann, Georg, additional, Platt, George, additional, Poirier, Germain, additional, Sokurenko, German, additional, Haddad, Ghassan, additional, Ali, Gholam, additional, Agnelli, Giancarlo, additional, Gan, Gin Gin, additional, Kaye-Eddie, Grace, additional, Le Gal, Gregoire, additional, Allen, Gregory, additional, Esperón, Guillermo Antonio Llamas, additional, Jean-Paul, Guillot, additional, Gerofke, Hagen, additional, Elali, Hallah, additional, Burianova, Hana, additional, Ohler, Hans-Juergen, additional, Wang, Haofu, additional, Darius, Harald, additional, Gogia, Harinder S., additional, Striekwold, Harry, additional, Hasanoglu, Hatice, additional, Turker, Hatice, additional, Franow, Hendrik, additional, De Raedt, Herbert, additional, Schroe, Herman, additional, ElDin, Hesham Salah, additional, Zidan, Hesham, additional, Nakamura, Hiroaki, additional, Kim, Ho Young, additional, Lawall, Holger, additional, Zhu, Hong, additional, Tian, Hongyan, additional, Yhim, Ho-Young, additional, Hwang, Hun Gyu, additional, Shim, Hyeok, additional, Kim, Igor, additional, Libov, Igor, additional, Sonkin, Igor, additional, Suchkov, Igor, additional, Song, Ik-Chan, additional, Kiris, Ilker, additional, Staroverov, Ilya, additional, Looi, Irene, additional, De La Azuela Tenorio, Isabel M., additional, Savas, Ismail, additional, Gordeev, Ivan, additional, Podpera, Ivo, additional, Lee, Jae Hoon, additional, Sathar, Jameela, additional, Welker, James, additional, Beyer-Westendorf, Jan, additional, Kvasnicka, Jan, additional, Vanwelden, Jan, additional, Kim, JangYong, additional, Svobodova, Jaromira, additional, Gujral, Jaspal, additional, Marino, Javier, additional, Galvar, Javier Tristan, additional, Kassis, Jeannine, additional, Kuo, Jen-Yuan, additional, Shih, Jhih-Yuan, additional, Kwon, JiHyun, additional, Joh, Jin Hyun, additional, Park, Jin Hyun, additional, Kim, Jin Seok, additional, Yang, Jinghua, additional, Krupicka, Jiri, additional, Lastuvka, Jiri, additional, Pumprla, Jiri, additional, Vesely, Jiri, additional, Souto, Joan Carlos, additional, Correa, João Antônio, additional, Duchateau, Johan, additional, Fletcher, John Perry, additional, del Toro, Jorge, additional, Paez, Jorge Guillermo Chavez, additional, Nielsen, Jørn, additional, Filho, Jose Dalmo Araujo, additional, Saraiva, Jose, additional, Peromingo, Jose Antonio Diaz, additional, Lara, Jose Gomez, additional, Fedele, Jose Luis, additional, Surinach, Jose Maria, additional, Chacko, Joseph, additional, Muntaner, Juan Antonio, additional, Benitez, Juan Carlos Álvarez, additional, Abril, Juan Moreno Hoyos, additional, Humphrey, Julian, additional, Bono, Julio, additional, Kanda, Junji, additional, Boondumrongsagoon, Juree, additional, Yiu, Kai Hang, additional, Chansung, Kanchana, additional, Boomars, Karin, additional, Burbury, Kate, additional, Kondo, Katsuhiro, additional, Karaarslan, Kemal, additional, Takeuchi, Kensuke, additional, Kroeger, Knut, additional, Zrazhevskiy, Konstantin, additional, Svatopluk, Koscál, additional, Shyu, Kou-Gi, additional, Vandenbosch, Kristel, additional, Chang, Kuan-Cheng, additional, Chiu, Kuan-Ming, additional, Jean-Manuel, Kubina, additional, Wern, Kwan Jing, additional, Ueng, Kwo-Chang, additional, Norasetthada, Lalita, additional, Binet, Laure, additional, Chew, Lee Ping, additional, Zhang, Lei, additional, Cristina, Leone Maria, additional, Tick, Lidwine, additional, Schiavi, Lilia Beatriz, additional, Wong, Lily Lee Lee, additional, Borges, Lohana, additional, Botha, Louis, additional, Capiau, Luc, additional, Timmermans, Luc, additional, López, Luciano Eduardo, additional, Ria, Luigi, additional, Blasco, Luis Manuel Hernandez, additional, Guzman, Luis Alberto, additional, Cervera, Luis Flota, additional, Isabelle, Mahe, additional, Bosch, Manuel Monreal, additional, de los Rios Ibarra, Manuel, additional, Fernandez, Manuel Núñez, additional, Carrier, Marc, additional, Barrionuevo, Marcelo Raul, additional, Gamba, Marco Antonio Alcocer, additional, Cattaneo, Marco, additional, Moia, Marco, additional, Bowers, Margaret, additional, Chetanachan, Mariam, additional, Berli, Mario Alberto, additional, Fixley, Mark, additional, Faghih, Markus, additional, Stuecker, Markus, additional, Schul, Marlin, additional, Banyai, Martin, additional, Koretzky, Martin, additional, Myriam, Martin, additional, Gaffney, Mary Elizabeth, additional, Hirano, Masao, additional, Kanemoto, Masashi, additional, Nakamura, Mashio, additional, Tahar, Mersel, additional, Emmanuel, Messas, additional, Kovacs, Michael, additional, Leahy, Michael, additional, Levy, Michael, additional, Munch, Michael, additional, Olsen, Michael, additional, De Pauw, Michel, additional, Gustin, Michel, additional, Van Betsbrugge, Michiel, additional, Boyarkin, Mikhail, additional, Homza, Miroslav, additional, Koto, Modise, additional, Abdool-Gaffar, Mohamed, additional, Nagib, Mohamed Ayman Fakhry, additional, El-Dessoki, Mohamed, additional, Khan, Mohamed, additional, Mohamed, Monniaty, additional, Kim, Moo Hyun, additional, Lee, Moon-Hee, additional, Soliman, Mosaad, additional, Ahmed, Mostafa Shawky, additional, el Bary, Mostafa Soliman Abd, additional, Moustafa, Moustafa A., additional, Hameed, Muhammad, additional, Kanko, Muhip, additional, Majumder, Mujibur, additional, Zubareva, Nadezhda, additional, Mumoli, Nicola, additional, Abdullah, Nik Azim Nik, additional, Makruasi, Nisa, additional, Paruk, Nishen, additional, Kanitsap, Nonglak, additional, Duda, Norberto, additional, Nordin, Nordiana, additional, Nyvad, Ole, additional, Barbarash, Olga, additional, Gurbuz, Orcun, additional, Vilamajo, Oscar Gomez, additional, Flores, Oscar Nandayapa, additional, Gur, Ozcan, additional, Oto, Oztekin, additional, Marchena, Pablo Javier, additional, Carroll, Patrick, additional, Lang, Pavel, additional, MacCallum, Peter, additional, von Bilderling, Peter Baron, additional, Blombery, Peter, additional, Jansky, Petr, additional, Bernadette, Peuch, additional, De Vleeschauwer, Philippe, additional, Hainaut, Philippe, additional, Ferrini, Piera Maria, additional, Iamsai, Piriyaporn, additional, Christian, Ponchaux, additional, Viboonjuntra, Pongtep, additional, Rojnuckarin, Ponlapat, additional, Ho, Prahlad, additional, Mutirangura, Pramook, additional, Wells, Rachel, additional, Martinez, Rafael, additional, Miranda, Raimundo Tirado, additional, Kroening, Ralf, additional, Ratsela, Rapule, additional, Reyes, Raquel Lopez, additional, de Leon, Raul Franco Diaz, additional, Wong, Raymond Siu Ming, additional, Alikhan, Raz, additional, Jerwan-Keim, Reinhold, additional, Otero, Remedios, additional, Murena-Schmidt, Renate, additional, Canevascini, Reto, additional, Ferkl, Richard, additional, White, Richard, additional, Van Herreweghe, Rika, additional, Santoro, Rita, additional, Klamroth, Robert, additional, Mendes, Robert, additional, Prosecky, Robert, additional, Cappelli, Roberto, additional, Spacek, Rudolf, additional, Singh, Rupesh, additional, Griffin, Sam, additional, Na, Sang Hoon, additional, Chunilal, Sanjeev, additional, Middeldorp, Saskia, additional, Nakazawa, Satoshi, additional, Toh, See Guan, additional, Christophe, Seinturier, additional, Isbir, Selim, additional, Raymundo, Selma, additional, Ting, Seng Kiat, additional, Motte, Serge, additional, Aktogu, Serir Ozkan, additional, Donders, Servaas, additional, Cha, Seung Ick, additional, Nam, Seung-Hyun, additional, Marie-Antoinette, Sevestre-Pietri, additional, Maasdorp, Shaun, additional, Sun, Shenghua, additional, Wang, Shenming, additional, Essameldin, Sherif Mohamed, additional, Sholkamy, Sherif Mohamed, additional, Kuki, Shintaro, additional, Yoshida, Shuichi, additional, Matsuoka, Shunzo, additional, McRae, Simon, additional, Watt, Simon, additional, Patanasing, Siriwimon, additional, Jean-Léopold, Siwe-Nana, additional, Wongkhantee, Somchai, additional, Bang, Soo-Mee, additional, Testa, Sophie, additional, Zemek, Stanislav, additional, Behrens, Steffen, additional, Dominique, Stephan, additional, Mellor, Stuart, additional, Singh, Suaran Singh Gurcharan, additional, Datta, Sudip, additional, Chayangsu, Sunee, additional, Solymoss, Susan, additional, Everington, Tamara, additional, Abdel-Azim, Tarek Ahmed Adel, additional, Suwanban, Tawatchai, additional, Adademir, Taylan, additional, Hart, Terence, additional, Béatrice, Terriat, additional, Luvhengo, Thifhelimbilu, additional, Horacek, Thomas, additional, Zeller, Thomas, additional, Boussy, Tim, additional, Reynolds, Tim, additional, Biss, Tina, additional, Chao, Ting-Hsing, additional, Casabella, Tomas Smith, additional, Onodera, Tomoya, additional, Numbenjapon, Tontanai, additional, Gerdes, Victor, additional, Cech, Vladimir, additional, Krasavin, Vladimir, additional, Tolstikhin, Vladimir, additional, Bax, W.A., additional, Malek, Wagih Fawzy Abdel, additional, Ho, Wai Khoon, additional, Pharr, Walter, additional, Jiang, Weihong, additional, Lin, Wei-Hsiang, additional, Zhang, Weihua, additional, Tseng, Wei-Kung, additional, Lai, Wen-Ter, additional, De Backer, Wilfried, additional, Haverkamp, Wilhelm, additional, Yoshida, Winston, additional, Korte, Wolfgang, additional, Choi, Won Il, additional, Kim, Yang-Ki, additional, Tanabe, Yasuhiro, additional, Ohnuma, Yasushi, additional, Mun, Yeung-Chul, additional, Balthazar, Yohan, additional, Park, Yong, additional, Shibata, Yoshisato, additional, Burov, Yuriy, additional, Subbotin, Yuriy, additional, Coufal, Zdenek, additional, Yang, Zhenwen, additional, Jing, Zhicheng, additional, and Yang, Zhongqi, additional

Published
2023
Full Text
View/download PDF

48. Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer

Author

Gudenkauf, Lisa M., primary, Chavez, Melody N., additional, Maconi, Melinda Leigh, additional, Geiss, Carley, additional, Seyedroudbari, Ameen, additional, Thin, Pan, additional, Hoogland, Aasha I., additional, Nguyen, Kathleen, additional, Murthy, Vishnu, additional, Armstrong, Wesley R., additional, Komrokji, Khaled, additional, Oswald, Laura B., additional, Jim, Heather S.L., additional, El-Haddad, Ghassan, additional, Fendler, Wolfgang P., additional, Herrmann, Ken, additional, Cella, David, additional, Czernin, Johannes, additional, Hofman, Michael S., additional, Dicker, Adam P., additional, Calais, Jeremie, additional, Tagawa, Scott T., additional, and Gonzalez, Brian D., additional

Published
2023
Full Text
View/download PDF

50. 1132 Impact of intralesional oncolytic viral therapy targetingin situactivation of CD40 and type 1 interferon signaling pathways on the TME and systemic T cell immunity in murine models and cancer patients

Author

Saltos, Andreas, primary, Zheng, Hong, additional, Arrowood, Christy, additional, Beasley, Georgia, additional, Ronald, James, additional, El-Haddad, Ghassan, additional, Khan, Uzma, additional, Guerra-Guevara, Luiziane, additional, Wolf, Steven, additional, Gu, Lin, additional, Wang, Xiaofei, additional, Cantwell, Mark, additional, Antonia, Scott, additional, Beg, Amer, additional, and Ready, Neal, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results